pentoksifillina | Trental 400 tablets, prolonged d-viya covered captive.ob. 400 mg 60 pcs.
Special Price
$37.72
Regular Price
$50.00
In stock
SKU
BID467284
Release form
sustained release coated tablets
sustained release coated tablets
Release form
sustained release coated tablets
Packing
60 pcs.
Pharmacological action
Trental - normalizes the rheological properties of blood, improves microcirculation, vasodilator.
Pharmacodynamics
Trental improves the rheological properties of blood (fluidity) by acting on the pathologically altered deformability of red blood cells, inhibiting platelet aggregation and reducing increased blood viscosity. Trental improves microcirculation in areas of impaired circulation.
As an active ingredient, Trental contains a xanthine derivative - pentoxifylline. The mechanism of its action is associated with the inhibition of phosphodiesterase and the accumulation of cAMP in the smooth muscle cells of blood vessels and blood cells.
Having a weak myotropic vasodilator effect, pentoxifylline somewhat reduces OPSS and slightly dilates the coronary vessels.
Treatment with Trental improves symptoms in cases of cerebrovascular accident.
The success of treatment for occlusive lesions of the peripheral arteries (for example, intermittent claudication) is manifested in lengthening the walking distance, eliminating night cramps in the calf muscles and the disappearance of pain at rest.
Pharmacokinetics
Tablets 100, 400 mg
After oral administration, pentoxifylline is rapidly and almost completely absorbed.
After almost complete absorption, pentoxifylline is metabolized. The absolute bioavailability of the starting substance is (19 ± 13)%. The main active metabolite 1- (5-hydroxyhexyl) -3,7-dimethylxanthine (metabolite-1) has a plasma concentration of 2 times the initial concentration of pentoxifylline.
T1 / 2 of pentoxifylline after oral administration is 1.6 hours.
Pentoxifylline is completely metabolized, more than 90% is excreted through the kidneys in the form of unconjugated water-soluble metabolites. Excretion of metabolites is delayed in patients with impaired renal function.
In patients with impaired liver function, T1 / 2 of pentoxifylline lengthens and absolute bioavailability increases.
Solution for infusion
Pentoxifylline is extensively metabolized in red blood cells and the liver. Among the most famous metabolites, metabolite-1 (M-1 hydroxypentoxifylline) is formed due to cleavage, and metabolite-4 (M-IV) and metabolite-5 (MV carboxypentoxyphylline) due to the oxidation of the main substance. M-l has the same pharmacological activity as pentoxifylline. More than 90% of the dose of pentoxifylline taken is excreted through the kidneys and 3-4% with feces.
T1 / 2 of pentoxifylline after iv administration of 100 mg was approximately 1.1 hours. In patients with severely impaired hepatic function, T1 / 2 of pentoxifylline is increased. Pentoxifylline has a large volume of distribution (168 L after 30 min infusion of 200 mg) and a high clearance of approximately 4,500-5100 ml / min. Pentoxifylline and its metabolites do not bind to plasma proteins. In severe renal impairment, excretion of metabolites is slowed down.
Contraindications
Hypersensitivity to the components of the
preparation massive bleeding
extensive hemorrhage in the eye
cerebral hemorrhage
acute myocardial infarction
severe arrhythmias arrhythmia chronic arrhythmias arrhythmia arrhythmias arrhythmia severe lactation (breastfeeding)
hypersensitivity to other methylxanthines.
Caution should be used in patients with: arterial hypotension (risk of lowering blood pressure), chronic heart failure, impaired renal function - QC less than 30 ml / min (risk of cumulation and increased risk of side effects), with severe impaired liver function (risk of cumulation and an increased risk of side effects), an increased tendency to bleeding, including as a result of the use of anticoagulants or with disorders of the blood coagulation system (risk of more severe bleeding), after recent surgery.
Special instructions
Careful monitoring is necessary in patients with severe cardiac arrhythmias (risk of worsening arrhythmias), with arterial hypotension (risk of further decrease in blood pressure), impaired renal function in patients with CC less than 30 ml / min (risk of cumulation and increased risk of side effects ), severe impaired liver function (risk of cumulation and an increased risk of side effects) and an increased tendency to bleeding, for example, with the use of anticoagulants or with violations in the blood coagulation system (risk of developing more severe bleeding).
Caution should be exercised when prescribing Trental to patients with gastric and duodenal ulcer in the history of patients who have recently undergone surgery (increased risk of bleeding, which requires systematic monitoring of hemoglobin and hematocrit).
In patients with arterial hypotension and labile circulation, parenteral administration of Trental is prescribed gradually, since a decrease in blood pressure (up to collapse) is possible, and in some cases, angina attacks.
Patients with heart failure need appropriate treatment to compensate for blood circulation. In this case, the introduction of a large volume of liquids should be avoided.
In patients with impaired renal function, the dosage regimen should be selected individually.
Composition
1 tablet contains:
Active e substance: pentoxifylline
400 mg Excipients: hydroxyethylcellulose, polyvinylpyrrolidone, talc, magnesium stearate, hydroxypropyl methylcellulose, benzyl alcohol, polyethylene glycol 6000, titanium dioxide.
Dosage and administration
Inside, swallowed whole, during or immediately after a meal, with plenty of water. The dosage is set by the doctor in accordance with the individual characteristics of the patient.
Usual dose - 1 tablet of Trental® 400 2 or 3 times a day. The maximum daily dose is 1200 mg.
In patients with impaired renal function (creatinine Cl below 30 ml / min), the dosage can be reduced to 1-2 tablets per day.
Dose reduction, taking into account individual tolerance, is necessary in patients with severe hepatic impairment.
Treatment can be started in small doses in patients with low blood pressure, as well as in people at risk due to a possible decrease in blood pressure (patients with severe coronary artery disease or hemodynamically significant stenosis of the cerebral vessels). In these cases, the dose can only be increased gradually.
Side effects
From the nervous system: headache, dizziness, anxiety, sleep disturbances, cramps.
From the skin and subcutaneous fat: flushing of the skin, flushing of the face and upper chest, swelling, increased fragility of the nails.
From the digestive system: xerostomia, anorexia, intestinal atony, a feeling of pressure and overflow in the stomach, nausea, vomiting, diarrhea.
From the cardiovascular system: tachycardia, arrhythmia, cardialgia, progression of angina pectoris, decreased blood pressure.
On the part of the hemostatic system and hematopoietic organs: leukopenia, thrombocytopenia, pancytopenia, bleeding from blood vessels of the skin, mucous membranes, stomach, intestines, hypofibrinogenemia.
On the part of the sensory organs: impaired vision, scotoma.
Allergic reactions: itching, flushing of the skin, urticaria, angioedema, anaphylactic shock.
Drug Interactions
When used together, Trental potentiates the action of a number of antihypertensive and hypoglycemic agents (both insulin and oral hypoglycemic drugs).
The simultaneous use of pentoxifylline and theophylline can lead to an increase in theophylline levels in the blood and increase its side effects.
Overdose
Symptoms: dizziness, vomiting, blood pressure drop, tachycardia, arrhythmia, redness of the skin, loss of consciousness, chills, areflexia, tonic-clonic convulsions. If you develop the symptoms mentioned above, you should seek immediate medical attention.
Treatment: symptomatic. Particular attention should be given to maintaining blood pressure and respiratory function. Convulsive seizures are removed by the introduction of diazepam. When the first signs of overdose (excessive sweating, nausea, cyanosis) immediately discontinue the drug. Provide lower head and upper torso position. Free airway is monitored.
Store
in a cool, dry place.
Shelf life
4 years
Deystvuyushtee substance
pentoxifylline
Terms and conditions
prescription
dosage form
tablets
Prescribing
Prescribing
Adults doctor's prescription
Sanofi India Ltd, India
sustained release coated tablets
Packing
60 pcs.
Pharmacological action
Trental - normalizes the rheological properties of blood, improves microcirculation, vasodilator.
Pharmacodynamics
Trental improves the rheological properties of blood (fluidity) by acting on the pathologically altered deformability of red blood cells, inhibiting platelet aggregation and reducing increased blood viscosity. Trental improves microcirculation in areas of impaired circulation.
As an active ingredient, Trental contains a xanthine derivative - pentoxifylline. The mechanism of its action is associated with the inhibition of phosphodiesterase and the accumulation of cAMP in the smooth muscle cells of blood vessels and blood cells.
Having a weak myotropic vasodilator effect, pentoxifylline somewhat reduces OPSS and slightly dilates the coronary vessels.
Treatment with Trental improves symptoms in cases of cerebrovascular accident.
The success of treatment for occlusive lesions of the peripheral arteries (for example, intermittent claudication) is manifested in lengthening the walking distance, eliminating night cramps in the calf muscles and the disappearance of pain at rest.
Pharmacokinetics
Tablets 100, 400 mg
After oral administration, pentoxifylline is rapidly and almost completely absorbed.
After almost complete absorption, pentoxifylline is metabolized. The absolute bioavailability of the starting substance is (19 ± 13)%. The main active metabolite 1- (5-hydroxyhexyl) -3,7-dimethylxanthine (metabolite-1) has a plasma concentration of 2 times the initial concentration of pentoxifylline.
T1 / 2 of pentoxifylline after oral administration is 1.6 hours.
Pentoxifylline is completely metabolized, more than 90% is excreted through the kidneys in the form of unconjugated water-soluble metabolites. Excretion of metabolites is delayed in patients with impaired renal function.
In patients with impaired liver function, T1 / 2 of pentoxifylline lengthens and absolute bioavailability increases.
Solution for infusion
Pentoxifylline is extensively metabolized in red blood cells and the liver. Among the most famous metabolites, metabolite-1 (M-1 hydroxypentoxifylline) is formed due to cleavage, and metabolite-4 (M-IV) and metabolite-5 (MV carboxypentoxyphylline) due to the oxidation of the main substance. M-l has the same pharmacological activity as pentoxifylline. More than 90% of the dose of pentoxifylline taken is excreted through the kidneys and 3-4% with feces.
T1 / 2 of pentoxifylline after iv administration of 100 mg was approximately 1.1 hours. In patients with severely impaired hepatic function, T1 / 2 of pentoxifylline is increased. Pentoxifylline has a large volume of distribution (168 L after 30 min infusion of 200 mg) and a high clearance of approximately 4,500-5100 ml / min. Pentoxifylline and its metabolites do not bind to plasma proteins. In severe renal impairment, excretion of metabolites is slowed down.
Contraindications
Hypersensitivity to the components of the
preparation massive bleeding
extensive hemorrhage in the eye
cerebral hemorrhage
acute myocardial infarction
severe arrhythmias arrhythmia chronic arrhythmias arrhythmia arrhythmias arrhythmia severe lactation (breastfeeding)
hypersensitivity to other methylxanthines.
Caution should be used in patients with: arterial hypotension (risk of lowering blood pressure), chronic heart failure, impaired renal function - QC less than 30 ml / min (risk of cumulation and increased risk of side effects), with severe impaired liver function (risk of cumulation and an increased risk of side effects), an increased tendency to bleeding, including as a result of the use of anticoagulants or with disorders of the blood coagulation system (risk of more severe bleeding), after recent surgery.
Special instructions
Careful monitoring is necessary in patients with severe cardiac arrhythmias (risk of worsening arrhythmias), with arterial hypotension (risk of further decrease in blood pressure), impaired renal function in patients with CC less than 30 ml / min (risk of cumulation and increased risk of side effects ), severe impaired liver function (risk of cumulation and an increased risk of side effects) and an increased tendency to bleeding, for example, with the use of anticoagulants or with violations in the blood coagulation system (risk of developing more severe bleeding).
Caution should be exercised when prescribing Trental to patients with gastric and duodenal ulcer in the history of patients who have recently undergone surgery (increased risk of bleeding, which requires systematic monitoring of hemoglobin and hematocrit).
In patients with arterial hypotension and labile circulation, parenteral administration of Trental is prescribed gradually, since a decrease in blood pressure (up to collapse) is possible, and in some cases, angina attacks.
Patients with heart failure need appropriate treatment to compensate for blood circulation. In this case, the introduction of a large volume of liquids should be avoided.
In patients with impaired renal function, the dosage regimen should be selected individually.
Composition
1 tablet contains:
Active e substance: pentoxifylline
400 mg Excipients: hydroxyethylcellulose, polyvinylpyrrolidone, talc, magnesium stearate, hydroxypropyl methylcellulose, benzyl alcohol, polyethylene glycol 6000, titanium dioxide.
Dosage and administration
Inside, swallowed whole, during or immediately after a meal, with plenty of water. The dosage is set by the doctor in accordance with the individual characteristics of the patient.
Usual dose - 1 tablet of Trental® 400 2 or 3 times a day. The maximum daily dose is 1200 mg.
In patients with impaired renal function (creatinine Cl below 30 ml / min), the dosage can be reduced to 1-2 tablets per day.
Dose reduction, taking into account individual tolerance, is necessary in patients with severe hepatic impairment.
Treatment can be started in small doses in patients with low blood pressure, as well as in people at risk due to a possible decrease in blood pressure (patients with severe coronary artery disease or hemodynamically significant stenosis of the cerebral vessels). In these cases, the dose can only be increased gradually.
Side effects
From the nervous system: headache, dizziness, anxiety, sleep disturbances, cramps.
From the skin and subcutaneous fat: flushing of the skin, flushing of the face and upper chest, swelling, increased fragility of the nails.
From the digestive system: xerostomia, anorexia, intestinal atony, a feeling of pressure and overflow in the stomach, nausea, vomiting, diarrhea.
From the cardiovascular system: tachycardia, arrhythmia, cardialgia, progression of angina pectoris, decreased blood pressure.
On the part of the hemostatic system and hematopoietic organs: leukopenia, thrombocytopenia, pancytopenia, bleeding from blood vessels of the skin, mucous membranes, stomach, intestines, hypofibrinogenemia.
On the part of the sensory organs: impaired vision, scotoma.
Allergic reactions: itching, flushing of the skin, urticaria, angioedema, anaphylactic shock.
Drug Interactions
When used together, Trental potentiates the action of a number of antihypertensive and hypoglycemic agents (both insulin and oral hypoglycemic drugs).
The simultaneous use of pentoxifylline and theophylline can lead to an increase in theophylline levels in the blood and increase its side effects.
Overdose
Symptoms: dizziness, vomiting, blood pressure drop, tachycardia, arrhythmia, redness of the skin, loss of consciousness, chills, areflexia, tonic-clonic convulsions. If you develop the symptoms mentioned above, you should seek immediate medical attention.
Treatment: symptomatic. Particular attention should be given to maintaining blood pressure and respiratory function. Convulsive seizures are removed by the introduction of diazepam. When the first signs of overdose (excessive sweating, nausea, cyanosis) immediately discontinue the drug. Provide lower head and upper torso position. Free airway is monitored.
Store
in a cool, dry place.
Shelf life
4 years
Deystvuyushtee substance
pentoxifylline
Terms and conditions
prescription
dosage form
tablets
Prescribing
Prescribing
Adults doctor's prescription
Sanofi India Ltd, India
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review